The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Cann Global (CGB) shares jump after its cannabis hard pills were received in Australia
  • Cann began importing the cannabis pills in late March following the green light by Health Canada
  • Currently, two of its six products have been shipped, with the remaining four arriving soon
  • The cannabidiol formulations will be available for ordering by pharmacies once the shipment has been cleared in customs
  • On market close, Cann is up 20 per cent and trading at 0.6 cents per share

Cann Global (CGB) shares jumped today after its cannabis hard pills were received in Australia.

The company launched its products last October with its Canadian joint venture partner Canntab Therapeutics.

Cann began importing the cannabis pills in late March after receiving the green light by Health Canada.

Currently, two of its six products have been shipped, with the remaining four arriving soon.

According to Cann, its products are unique because of the patented hard pill form in which they come in, allowing for more precise dosing.

The cannabidiol formulations will be available for ordering by pharmacies once the shipment has been cleared in customs.

“The products can be prescribed by practitioners via the Special Access Scheme Category B application pathway,” the company told the market.

Cann Global will update the market when the remaining four products have arrived in Australia.

On market close, Cann is up 20 per cent and trading at 0.6 cents per share.


cgb by the numbers
More From The Market Online

LTR Pharma expands men’s health portfolio with KYZATREX pilot

LTR Pharma has entered into an exclusive pilot agreement to introduce KYZATREX oral testosterone capsules in…

4DMedical posts FY26 revenue growth as commercial deployment ramps up

4DMedical reports 21% FY26 revenue growth as CT:VQ gains commercial adoption, global regulatory approvals and major…

Patrys secures ethics approval for Phase 1A clinical trial on delirium candidate

Patrys has received HREC approval to commence its Phase 1A clinical trial of RLS-2202 for the…

Ramsay Health Care profit surges as Australian hospitals drive FY26 turnaround

Ramsay Health Care reports a sharp FY26 profit increase, with stronger Australian hospital activity, improved margins…